Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyCellularComponent	histone acetyltransferase complex	SUPT20HL1 SUPT20HL2 ACTL6A KANSL1 ATXN7	2.63e-04	94	126	5	GO:0000123
GeneOntologyCellularComponent	protein acetyltransferase complex	SUPT20HL1 SUPT20HL2 ACTL6A KANSL1 ATXN7	4.20e-04	104	126	5	GO:0031248
GeneOntologyCellularComponent	azurophil granule	ABCA13 SYNGR1 CPNE3 CPNE1 MAPK1 GNS	4.23e-04	160	126	6	GO:0042582
GeneOntologyCellularComponent	primary lysosome	ABCA13 SYNGR1 CPNE3 CPNE1 MAPK1 GNS	4.23e-04	160	126	6	GO:0005766
GeneOntologyCellularComponent	azurophil granule membrane	ABCA13 SYNGR1 CPNE3 CPNE1	4.43e-04	59	126	4	GO:0035577
GeneOntologyCellularComponent	SAGA complex	SUPT20HL1 SUPT20HL2 ATXN7	4.46e-04	25	126	3	GO:0000124
GeneOntologyCellularComponent	acetyltransferase complex	SUPT20HL1 SUPT20HL2 ACTL6A KANSL1 ATXN7	5.20e-04	109	126	5	GO:1902493
GeneOntologyCellularComponent	ficolin-1-rich granule	HUWE1 ITGB2 CD58 MAPK1 CTSH GNS	9.07e-04	185	126	6	GO:0101002
Domain	C2	ITCH OTOF CPNE3 CPNE1 UNC13C MCTP2	1.84e-04	131	118	6	PF00168
Domain	C2	ITCH OTOF CPNE3 CPNE1 UNC13C MCTP2	2.35e-04	137	118	6	SM00239
Domain	-	MMP21 MMP2	2.36e-04	4	118	2	1.10.101.10
Domain	C2	ITCH OTOF CPNE3 CPNE1 UNC13C MCTP2	2.85e-04	142	118	6	PS50004
Domain	UDPGT	UGT2B15 UGT2B17 UGT8	3.01e-04	21	118	3	PF00201
Domain	UDPGT	UGT2B15 UGT2B17 UGT8	3.01e-04	21	118	3	PS00375
Domain	UDP_glucos_trans	UGT2B15 UGT2B17 UGT8	3.01e-04	21	118	3	IPR002213
Domain	-	ITCH OTOF CPNE3 CPNE1 UNC13C MCTP2	3.56e-04	148	118	6	2.60.40.150
Pathway	REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	IGKV1-39 IGKV1-33 IGKV1-16 MAPK1 IGKV1D-39 IGKV1D-33 IGKV1D-16	2.04e-06	87	96	7	M27205
Pathway	REACTOME_CD22_MEDIATED_BCR_REGULATION	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	3.50e-06	61	96	6	M27581
Pathway	REACTOME_ANTI_INFLAMMATORY_RESPONSE_FAVOURING_LEISHMANIA_PARASITE_INFECTION	IGKV1-39 IGKV1-33 IGKV1-16 ADCY4 ADORA2B IGKV1D-39 IGKV1D-33 IGKV1D-16	3.55e-06	134	96	8	M29840
Pathway	REACTOME_FCGR3A_MEDIATED_IL10_SYNTHESIS	IGKV1-39 IGKV1-33 IGKV1-16 ADCY4 IGKV1D-39 IGKV1D-33 IGKV1D-16	3.69e-06	95	96	7	M29842
Pathway	REACTOME_FCGR_ACTIVATION	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	7.23e-06	69	96	6	M27108
Pathway	REACTOME_SCAVENGING_OF_HEME_FROM_PLASMA	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	7.23e-06	69	96	6	M27150
Pathway	REACTOME_CREATION_OF_C4_AND_C2_ACTIVATORS	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	8.54e-06	71	96	6	M1078
Pathway	REACTOME_ROLE_OF_LAT2_NTAL_LAB_ON_CALCIUM_MOBILIZATION	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	8.54e-06	71	96	6	M27203
Pathway	REACTOME_PARASITE_INFECTION	IGKV1-39 IGKV1-33 IGKV1-16 MAPK1 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.39e-05	116	96	7	M29843
Pathway	REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.71e-05	80	96	6	M6121
Pathway	REACTOME_LEISHMANIA_INFECTION	IGKV1-39 IGKV1-33 IGKV1-16 ADCY4 ADORA2B MAPK1 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.80e-05	219	96	9	M29836
Pathway	REACTOME_ROLE_OF_PHOSPHOLIPIDS_IN_PHAGOCYTOSIS	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.97e-05	82	96	6	M27110
Pathway	REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	2.58e-05	86	96	6	M601
Pathway	REACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	2.58e-05	86	96	6	M27206
Pathway	REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL	IGKV1-39 IGKV1-33 IGKV1-16 ITGB2 CD58 IGKV1D-39 IGKV1D-33 IGKV1D-16	5.25e-05	194	96	8	M16312
Pathway	REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS	IGKV1-39 IGKV1-33 IGKV1-16 MAPK1 IGKV1D-39 IGKV1D-33 IGKV1D-16	5.36e-05	143	96	7	M27107
Pathway	REACTOME_BINDING_AND_UPTAKE_OF_LIGANDS_BY_SCAVENGER_RECEPTORS	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	5.42e-05	98	96	6	M27152
Pathway	WP_IRINOTECAN_PATHWAY	ABCC1 CES1 CES2	6.44e-05	12	96	3	M39611
Pathway	REACTOME_COMPLEMENT_CASCADE	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.32e-04	115	96	6	M19752
Pathway	REACTOME_INNATE_IMMUNE_SYSTEM	IGKV1-39 IGKV1-33 IGKV1-16 ITCH RIPK3 ABCA13 HUWE1 ITGB2 SYNGR1 CPNE3 FGA CD58 CPNE1 MAPK1 IGKV1D-39 IGKV1D-33 IGKV1D-16 CTSH GNS	1.85e-04	1128	96	19	M1036
Pathway	REACTOME_ASPIRIN_ADME	CES1 CES2 UGT2B15 UGT2B17	2.23e-04	44	96	4	M45014
Pathway	REACTOME_ASPIRIN_ADME	CES1 CES2 UGT2B15 UGT2B17	2.43e-04	45	96	4	MM15694
Pathway	REACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING	IGKV1-39 IGKV1-33 IGKV1-16 MAPK1 IGKV1D-39 IGKV1D-33 IGKV1D-16	2.76e-04	186	96	7	M27175
Pathway	REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL	IGKV1-39 IGKV1-33 IGKV1-16 ITGB2 IGKV1D-39 IGKV1D-33 IGKV1D-16	3.14e-04	190	96	7	M8240
Pathway	REACTOME_FCERI_MEDIATED_NF_KB_ACTIVATION	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	3.29e-04	136	96	6	M27207
Pathway	KEGG_DRUG_METABOLISM_OTHER_ENZYMES	CES1 CES2 UGT2B15 UGT2B17	3.95e-04	51	96	4	M17726
Pathway	REACTOME_SIGNALING_BY_NODAL	PCSK6 MAPK1 FOXH1	4.91e-04	23	96	3	M511
Pathway	REACTOME_POTENTIAL_THERAPEUTICS_FOR_SARS	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	6.37e-04	154	96	6	M39007
Pathway	REACTOME_DRUG_ADME	ABCC1 CES1 CES2 UGT2B15 UGT2B17	8.81e-04	109	96	5	M45012
Pathway	REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-39 IGKV1D-33 IGKV1D-16	9.42e-04	166	96	6	M608
Pathway	KEGG_MEDICUS_REFERENCE_BMP_HAMP_SIGNALING_PATHWAY_AUXILIARY_FACTOR	HFE BMPR2	9.43e-04	7	96	2	M47851
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	PRPF31 EPRS1 TTF2 DDX19A ITCH NPEPPS WDR70 DHX57 ACTL6A UPF1 HUWE1 DNTTIP2 HMGA2 KANSL1 CPNE3 BYSL HADHB WDFY3 MAPK1 FSCN1 NEXN PHIP TOP2A EPB41L2	2.87e-10	1353	132	24	29467282
Pubmed	FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.	IGKV1-39 IGKV1-33 PRPF31 IGKV1-16 NPEPPS RBM26 DHX57 ACTL6A LOXHD1 LGI2 FGA IGKV1D-39 IGKV1D-33 IGKV1D-16	7.27e-09	497	132	14	36774506
Pubmed	Characteristics of the immunoglobulin Vkappa genes, pseudogenes, relics and orphons in the mouse genome.	IGKV1-39 IGKV1-16 IGKV1D-43 IGKV1D-39 IGKV1D-33	1.08e-08	20	132	5	10427970
Pubmed	Amino acid sequence of the variable region of M149 mouse myeloma light chain: comparison with the nucleotide sequence of K2 and K3 clones.	IGKV1-39 IGKV1D-43 IGKV1D-39 IGKV1D-33	6.41e-08	11	132	4	6795447
Pubmed	Multiple related immunoglobulin variable-region genes identified by cloning and sequence analysis.	IGKV1-39 IGKV1D-43 IGKV1D-39 IGKV1D-33	6.41e-08	11	132	4	279004
Pubmed	Organization and complete sequence of identical embryonic and plasmacytoma kappa V-region genes.	IGKV1-39 IGKV1D-43 IGKV1D-39 IGKV1D-33	6.41e-08	11	132	4	6767723
Pubmed	Human myeloperoxidase in innate and acquired immunity.	IGKV1-39 IGKV1D-43 IGKV1D-39 IGKV1D-33	5.82e-07	18	132	4	20399194
Pubmed	The functional interactome landscape of the human histone deacetylase family.	TTF2 DDX19A ACTL6A HUWE1 DNTTIP2 CPNE3 RCOR3 DNAJB2 PHIP	1.73e-06	289	132	9	23752268
Pubmed	Variation in the crossover point of kappa immunoglobulin gene V-J recombination: evidence from a cryptic gene.	IGKV1-39 IGKV1-16 IGKV1D-39	4.41e-06	9	132	3	6777049
Pubmed	Irinotecan pathway genotype analysis to predict pharmacokinetics.	ABCC1 CES1 CES2	6.29e-06	10	132	3	12960109
Pubmed	A forward genetics screen in mice identifies recessive deafness traits and reveals that pejvakin is essential for outer hair cell function.	USP53 LOXHD1 OTOF	6.29e-06	10	132	3	17329413
Pubmed	The functional interactome of PYHIN immune regulators reveals IFIX is a sensor of viral DNA.	TTF2 DHX57 UPF1 HUWE1 DNTTIP2 BYSL MPHOSPH10 FSCN1 PHIP	8.00e-06	349	132	9	25665578
Pubmed	Evolutionary dynamics of the human immunoglobulin kappa locus and the germline repertoire of the Vkappa genes.	IGKV1D-43 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.06e-05	36	132	4	11298326
Pubmed	Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.	CES1 CES2	1.43e-05	2	132	2	17537833
Pubmed	Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.	TET2 ASXL1	1.43e-05	2	132	2	24218140
Pubmed	Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver.	CES1 CES2	1.43e-05	2	132	2	19487248
Pubmed	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.	TET2 ASXL1	1.43e-05	2	132	2	26771811
Pubmed	Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.	CES1 CES2	1.43e-05	2	132	2	18983829
Pubmed	Expression of UDP Glucuronosyltransferases 2B15 and 2B17 is associated with methylation status in prostate cancer cells.	UGT2B15 UGT2B17	1.43e-05	2	132	2	32660355
Pubmed	Down-regulation of circular RNA ITCH and circHIPK3 in gastric cancer tissues.	ITCH HIPK3	1.43e-05	2	132	2	30866608
Pubmed	Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.	TET2 ASXL1	1.43e-05	2	132	2	20334914
Pubmed	The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence.	UGT2B15 UGT2B17	1.43e-05	2	132	2	1909870
Pubmed	The recurrent chromosomal translocation t(12;18)(q14~15;q12~21) causes the fusion gene HMGA2-SETBP1 and HMGA2 expression in lipoma and osteochondrolipoma.	HMGA2 SETBP1	1.43e-05	2	132	2	26202160
Pubmed	Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients.	ABCC1 CES1	1.43e-05	2	132	2	31698983
Pubmed	Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes.	CES1 CES2	1.43e-05	2	132	2	18305377
Pubmed	Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.	UGT2B15 UGT2B17	1.43e-05	2	132	2	24121496
Pubmed	Phage display of a human antibody against Clostridium tetani toxin.	IGKV1-39 IGKV1D-39	1.43e-05	2	132	2	7926831
Pubmed	Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study.	UGT2B15 UGT2B17	1.43e-05	2	132	2	24267955
Pubmed	Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.	TET2 ASXL1	1.43e-05	2	132	2	37288803
Pubmed	Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.	UGT2B15 UGT2B17	1.43e-05	2	132	2	22170718
Pubmed	Predominant contributions of carboxylesterase 1 and 2 in hydrolysis of anordrin in humans.	CES1 CES2	1.43e-05	2	132	2	28532270
Pubmed	Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation.	MAPK1 TOP2A	1.43e-05	2	132	2	10207078
Pubmed	Different inhibitory effects in rat and human carboxylesterases.	CES1 CES2	1.43e-05	2	132	2	19225040
Pubmed	Localization of UDP glucuronosyltransferase gene(s) on mouse chromosome 5.	UGT2B15 UGT2B17	1.43e-05	2	132	2	3105095
Pubmed	Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.	ABCC1 TOP2A	1.43e-05	2	132	2	26617887
Pubmed	UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.	UGT2B15 UGT2B17	1.43e-05	2	132	2	17848572
Pubmed	Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.	CES1 CES2	1.43e-05	2	132	2	20649590
Pubmed	Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.	UGT2B15 UGT2B17	1.43e-05	2	132	2	27496708
Pubmed	ERK2-topoisomerase II regulatory axis is important for gene activation in immediate early genes.	MAPK1 TOP2A	1.43e-05	2	132	2	38097570
Pubmed	TET2 rs2454206, TET2 rs12498609 and ASXL1 rs3746609 single nucleotide polymorphisms in patients with myelodysplastic syndromes.	TET2 ASXL1	1.43e-05	2	132	2	30454965
Pubmed	The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.	UGT2B15 UGT2B17	1.43e-05	2	132	2	17698910
Pubmed	Carboxylesterase in the liver and small intestine of experimental animals and human.	CES1 CES2	1.43e-05	2	132	2	17764701
Pubmed	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.	ASXL1 SETBP1	1.43e-05	2	132	2	24695057
Pubmed	Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.	CES1 CES2	1.43e-05	2	132	2	15475733
Pubmed	Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.	CES1 CES2	1.43e-05	2	132	2	24212379
Pubmed	Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.	TET2 ASXL1	1.43e-05	2	132	2	23009937
Pubmed	Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny.	CES1 CES2	1.43e-05	2	132	2	26825642
Pubmed	Genes that mediate breast cancer metastasis to lung.	ANGPTL4 FSCN1	1.43e-05	2	132	2	16049480
Pubmed	Pharmacogenomic assessment of carboxylesterases 1 and 2.	CES1 CES2	1.43e-05	2	132	2	15475243
Pubmed	Mutations of ASXL1 and TET2 in aplastic anemia.	TET2 ASXL1	1.43e-05	2	132	2	25596262
Pubmed	Mouse UDP glucuronosyltransferase. cDNA and complete amino acid sequence and regulation.	UGT2B15 UGT2B17	1.43e-05	2	132	2	3117546
Pubmed	Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.	TET2 ASXL1	1.43e-05	2	132	2	26095772
Pubmed	ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.	TET2 ASXL1	1.43e-05	2	132	2	24465546
Pubmed	Histone H2A phosphorylation recruits topoisomerase IIα to centromeres to safeguard genomic stability.	BUB1 TOP2A	1.43e-05	2	132	2	31769059
Pubmed	Comprehensive Characterization of Mouse UDP-Glucuronosyltransferase (Ugt) Belonging to the Ugt2b Subfamily: Identification of Ugt2b36 as the Predominant Isoform Involved in Morphine Glucuronidation.	UGT2B15 UGT2B17	1.43e-05	2	132	2	28228532
Pubmed	Examination of the carboxylesterase phenotype in human liver.	CES1 CES2	1.43e-05	2	132	2	22525521
Pubmed	The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.	TET2 ASXL1	1.43e-05	2	132	2	35306971
Pubmed	Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium.	UGT2B15 UGT2B17	1.43e-05	2	132	2	15666817
Pubmed	USP53 plays an antitumor role in hepatocellular carcinoma through deubiquitination of cytochrome c.	USP53 PRPF31 EPRS1 DNTTIP2 CTSH	2.48e-05	90	132	5	35654790
Pubmed	Structure and implied functions of truncated B-cell receptor mRNAs in early embryo and adult mesenchymal stem cells: Cdelta replaces Cmu in mu heavy chain-deficient mice.	IGKV1-39 IGKV1-16 IGKV1D-39	2.89e-05	16	132	3	17124007
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	PRPF31 EPRS1 DDX19A ADCY4 MCMBP NPEPPS RBM26 ACTL6A UPF1 HUWE1 DNTTIP2 BYSL HADHB PHIP TOP2A EPB41L2 MCOLN2	2.94e-05	1425	132	17	30948266
Pubmed	Global genetic analysis in mice unveils central role for cilia in congenital heart disease.	MMP21 BMPR2 PCSK6 FOXH1 DNAH11	4.12e-05	100	132	5	25807483
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	NPEPPS DHX57 UPF1 HUWE1 DNTTIP2 BYSL SCAF11 MPHOSPH10 FSCN1 PHIP EPB41L2	4.18e-05	653	132	11	22586326
Pubmed	Interactions of the Antiviral Factor Interferon Gamma-Inducible Protein 16 (IFI16) Mediate Immune Signaling and Herpes Simplex Virus-1 Immunosuppression.	DHX57 UPF1 HUWE1 DNTTIP2 BYSL MPHOSPH10 PHIP TOP2A	4.18e-05	332	132	8	25693804
Pubmed	Catalog of 86 single-nucleotide polymorphisms (SNPs) in three uridine diphosphate glycosyltransferase genes: UGT2A1, UGT2B15, and UGT8.	UGT2B15 UGT8	4.28e-05	3	132	2	12376738
Pubmed	Supplemental Association of Clonal Hematopoiesis With Incident Heart Failure.	TET2 ASXL1	4.28e-05	3	132	2	34210413
Pubmed	Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism.	UGT2B15 UGT2B17	4.28e-05	3	132	2	19572376
Pubmed	Immunoglobulin genes of the kappa light chain type from two human lymphoid cell lines are closely related.	IGKV1-39 IGKV1D-39	4.28e-05	3	132	2	6091049
Pubmed	TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.	TET2 ASXL1	4.28e-05	3	132	2	23099237
Pubmed	Human carboxylesterases: an update on CES1, CES2 and CES3.	CES1 CES2	4.28e-05	3	132	2	19508181
Pubmed	Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.	UGT2B15 UGT2B17	4.28e-05	3	132	2	26385605
Pubmed	Activation of extracellular signal-related kinase in abdominal aortic aneurysm.	MMP2 MAPK1	4.28e-05	3	132	2	26988568
Pubmed	Human carboxylesterases in term placentae: enzymatic characterization, molecular cloning and evidence for the existence of multiple forms.	CES1 CES2	4.28e-05	3	132	2	10452915
Pubmed	[Relationship between DTA Mutations and Thromboembolism in Patients with Myeloproliferative Neoplasms].	TET2 ASXL1	4.28e-05	3	132	2	38926973
Pubmed	Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis.	TET2 ASXL1	4.28e-05	3	132	2	33803981
Pubmed	Mutations of ASXL1 gene in myeloproliferative neoplasms.	TET2 ASXL1	4.28e-05	3	132	2	19609284
Pubmed	Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.	TET2 ASXL1	4.28e-05	3	132	2	38231881
Pubmed	Expression and function of K(V)2-containing channels in human urinary bladder smooth muscle.	KCNB2 KCNS3	4.28e-05	3	132	2	22422395
Pubmed	Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease.	TET2 ASXL1	4.28e-05	3	132	2	34576030
Pubmed	SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.	ASXL1 SETBP1	4.28e-05	3	132	2	25306901
Pubmed	Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity.	CES1 CES2	4.28e-05	3	132	2	20195289
Pubmed	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.	TET2 ASXL1	4.28e-05	3	132	2	22489043
Pubmed	Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.	UGT2B15 UGT2B17	4.28e-05	3	132	2	26163549
Pubmed	Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells.	UGT2B15 UGT2B17	4.28e-05	3	132	2	20736324
Pubmed	Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.	UGT2B15 UGT2B17	4.28e-05	3	132	2	28882566
Pubmed	Clonal characterization of the human IgG antibody repertoire to Haemophilus influenzae type b polysaccharide. IV. The less frequently expressed VL are heterogeneous.	IGKV1-33 IGKV1D-33	4.28e-05	3	132	2	1940382
Pubmed	Significance of multidrug resistance gene-related proteins in the postoperative chemotherapy of gastric cancer.	ABCC1 TOP2A	4.28e-05	3	132	2	25550836
Pubmed	Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.	TET2 ASXL1	4.28e-05	3	132	2	34267355
Pubmed	Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: an ex vivo study.	MMP2 MAPK1	4.28e-05	3	132	2	20811691
Pubmed	Tissue expression of copines and isolation of copines I and III from the cytosol of human neutrophils.	CPNE3 CPNE1	4.28e-05	3	132	2	12949241
Pubmed	Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.	ASXL1 SETBP1	4.28e-05	3	132	2	37354804
Pubmed	Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.	UGT2B15 UGT2B17	4.28e-05	3	132	2	17988216
Pubmed	The p38-interacting protein (p38IP) regulates G2/M progression by promoting α-tubulin acetylation via inhibiting ubiquitination-induced degradation of the acetyltransferase GCN5.	SUPT20HL1 SUPT20HL2	4.28e-05	3	132	2	24220028
Pubmed	Tissue distribution and relative gene expression of UDP-glucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus.	UGT2B15 UGT2B17	4.28e-05	3	132	2	23223495
Pubmed	HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults.	TET2 ASXL1	4.28e-05	3	132	2	34099923
Pubmed	Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.	UGT2B15 UGT2B17	4.28e-05	3	132	2	18302198
Pubmed	The nuclear receptor Shp regulates morphine withdrawal syndrome via modulation of Ugt2b expression in mice.	UGT2B15 UGT2B17	4.28e-05	3	132	2	30689982
Pubmed	ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.	ASXL1 SETBP1	4.28e-05	3	132	2	25850813
Pubmed	Prediction of the coding sequences of unidentified human genes. XVIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.	TET2 GON4L ZBTB26 HUWE1 OGFOD1	4.32e-05	101	132	5	10997877
Pubmed	Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer.	RBM26 UPF1 HUWE1 EPB41L2	6.70e-05	57	132	4	38223760
Interaction	FBXO22 interactions	IGKV1-39 IGKV1-33 PRPF31 IGKV1-16 NPEPPS RBM26 DHX57 ACTL6A LOXHD1 LGI2 FGA IGKV1D-39 FSCN1 IGKV1D-33 IGKV1D-16	1.18e-06	540	124	15	int:FBXO22
Cytoband	2p12	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-43 IGKV1D-39 IGKV1D-33 IGKV1D-16	5.01e-08	117	131	7	2p12
Cytoband	Ensembl 112 genes in cytogenetic band chr2p11	IGKV1-39 IGKV1-33 IGKV1-16 ST3GAL5 IGKV1D-43 IGKV1D-39 IGKV1D-33 IGKV1D-16	2.00e-07	213	131	8	chr2p11
Cytoband	Xp22.11	SUPT20HL1 APOO SUPT20HL2	2.91e-05	21	131	3	Xp22.11
Cytoband	4q13	UGT2B15 UGT2B17	8.28e-04	15	131	2	4q13
GeneFamily	Immunoglobulin kappa locus at 2p11.2	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-43 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.83e-07	83	90	7	351
GeneFamily	Carboxylesterases	CES1 CES2	2.43e-04	5	90	2	461
GeneFamily	UDP glucuronosyltransferases	UGT2B15 UGT2B17 UGT8	5.33e-04	32	90	3	363
GeneFamily	Copines	CPNE3 CPNE1	8.62e-04	9	90	2	829
GeneFamily	Doublecortin superfamily	DCDC1 DCLK1	1.07e-03	10	90	2	1369
GeneFamily	Dyneins, axonemal	DNAH9 DNAH11	3.17e-03	17	90	2	536
GeneFamily	Aminopeptidases\|CD molecules	NPEPPS LNPEP	3.17e-03	17	90	2	104
Coexpression	DAZARD_RESPONSE_TO_UV_NHEK_DN	ASXL1 MED13L ADORA2B HMGA2 SCAF11 MPHOSPH10 WDFY3 MN1 PHIP USP6NL TOP2A	2.33e-07	300	126	11	M8702
Coexpression	RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP	EPRS1 ITCH ACTL6A DNTTIP2 ADORA2B ARHGAP5 HMGA2 LNPEP CD58 OGFOD1 MPHOSPH10 MAPK1 PHIP TOP2A	1.01e-05	721	126	14	M10237
Coexpression	GSE9960_HEALTHY_VS_GRAM_POS_SEPSIS_PBMC_DN	ITCH GPR19 APOO DNTTIP2 MPHOSPH10 MN1 MCOLN2	4.84e-05	197	126	7	M7121
Coexpression	GSE3337_CTRL_VS_4H_IFNG_IN_CD8POS_DC_UP	GON4L HUWE1 ITGB2 CAPRIN2 DNAJB2 GSTO1 CTSH	5.32e-05	200	126	7	M5097
Coexpression	OHGUCHI_LIVER_HNF4A_TARGETS_DN	CES1 CES2 HEBP1 UGT2B15 UGT2B17 AADAT CTSH	5.49e-05	201	126	7	MM1294
Coexpression	BROWN_MYELOID_CELL_DEVELOPMENT_UP	CCDC125 ITGB2 HEBP1 CPNE3 UGT2B15 UGT2B17 GNS	5.49e-05	201	126	7	MM1006
Coexpression	DESCARTES_FETAL_LUNG_CILIATED_EPITHELIAL_CELLS	MAK LRRIQ3 DCDC1 ABCA13 FANK1 LRRIQ1 UGT2B17 TMPRSS7 DNAH9 BTG4 DNAH11	6.17e-05	540	126	11	M40241
Coexpression	SHEPARD_CRASH_AND_BURN_MUTANT_UP	EPRS1 DDX19A MCMBP STARD10 ZNF622 DNTTIP2 MMP2	6.22e-05	205	126	7	M10828
CoexpressionAtlas	DevelopingKidney_e15.5_anlage of loop of Henle_emap-31283_k-means-cluster#3_top-relative-expression-ranked_1000	APOO ABCA13 HUWE1 HIPK3 KANSL1 LNPEP UGT8 MPHOSPH10 FSCN1 GARRE1 DCLK1	1.41e-05	379	124	11	gudmap_developingKidney_e15.5_1000_k3
ToppCell	COPD-Multiplet-Multiplet\|COPD / Disease state, Lineage and Cell class	MAGI1 DCDC1 ABCA13 FANK1 LRRIQ1 MCTP2 DNAH9 TOP2A DNAH11	6.57e-09	196	130	9	af4cdc61830685a888a1209826c23bcf54a43084
ToppCell	COPD-Multiplet\|COPD / Disease state, Lineage and Cell class	MAGI1 DCDC1 ABCA13 FANK1 LRRIQ1 MCTP2 DNAH9 TOP2A DNAH11	6.57e-09	196	130	9	6d02d494196e3f857d53eea46d9419690d43beca
ToppCell	Healthy-Plasmablast\|Healthy / disease group, cell group and cell class	IGKV1-16 BUB1 UGT2B17 UNC13C IGKV1D-39 IGKV1D-33 IGKV1D-16 DEPDC1B	5.28e-08	177	130	8	4ff75c609ac9edf7a94bda42eb7124c559e8b6aa
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGKV1-39 IGKV1-33 IGKV1-16 UGT2B17 IGKV1D-43 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.11e-07	195	130	8	f3f7f1a77a1edd2b50a8211c76fe289738eb04cf
ToppCell	3'-Broncho-tracheal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.0.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAK DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	6.67e-07	169	130	7	14aadc2d1bf66eb47dac33b4d61ddb3c942caa4f
ToppCell	3'-Broncho-tracheal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)-Multiciliated_(nasal)_L.0.3.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAK DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	9.45e-07	178	130	7	3b12db04006db6e94fc45649a4b3a63b92f21a61
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KALRN ABCA13 PIEZO2 LOXHD1 UNC13C DNAH9 DNAH11	1.18e-06	184	130	7	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KALRN ABCA13 PIEZO2 LOXHD1 UNC13C DNAH9 DNAH11	1.18e-06	184	130	7	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KALRN ABCA13 PIEZO2 LOXHD1 UNC13C DNAH9 DNAH11	1.18e-06	184	130	7	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DCDC1 ABCA13 LRRIQ1 LGI2 WDFY3 MCTP2 DNAH11	1.27e-06	186	130	7	5c4ffe4e4d5536ae9f8794277fe032c693e7dd56
ToppCell	368C-Lymphocytic-NK_cells-NK_cell_D3\|368C / Donor, Lineage, Cell class and subclass (all cells)	IGKV1-39 TTF2 NDUFAF5 WDR70 ARHGAP5 PCSK6 MAPK1	1.36e-06	188	130	7	ecc2364d946f97ae0212fd6739960c9fc75e4919
ToppCell	COVID-19-lung-Ciliated\|COVID-19 / Disease (COVID-19 only), tissue and cell type	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 BTG4 DNAH11	1.41e-06	189	130	7	a2da5debd10f27b1280b40141ef0bfef007cc72c
ToppCell	Mesenchymal-matrix_fibroblast_2_cell\|World / Lineage, Cell type, age group and donor	GXYLT2 PIEZO2 SETBP1 MMP2 MN1 DCLK1 EPB41L2	1.57e-06	192	130	7	a769158c49d2b208c4224d85e7ae68c85cc372ed
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGKV1-39 IGKV1-33 IGKV1-16 UGT2B17 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.74e-06	195	130	7	13f4ee21568fd747608412d33559d10561dbb3c8
ToppCell	NS-critical-LOC-Epithelial-Ciliated\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	DCDC1 CES1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.74e-06	195	130	7	34e37cff4849696ca4ba5dd8fd2cf98fed8bc912
ToppCell	COVID-19-Fibroblasts-Intermediate_pathological_FB\|COVID-19 / group, cell type (main and fine annotations)	KALRN GXYLT2 PIEZO2 SETBP1 MMP2 DCLK1 EPB41L2	1.86e-06	197	130	7	f1c8936986123a3151140c374fcd62d6705c530b
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_airway_ciliated-Deuterosomal\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	MAK DCDC1 FANK1 BUB1 DNAH9 TOP2A DNAH11	1.86e-06	197	130	7	861e8df9bd74dc5e17bafdc1fb3fef546753c73a
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGKV1-39 IGKV1-33 IGKV1-16 IGKV1D-43 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.86e-06	197	130	7	9fe1b757f76c2d43d39aa9ac500eaba98723985c
ToppCell	Bronchial-NucSeq-Endothelial-Endothelia_lymphatic-Endothelia_Lymphatic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MAGI1 ADCY4 KALRN PIEZO2 LOXHD1 PCSK6 EPB41L2	1.92e-06	198	130	7	b3a020522e064bb61949d38e442f24026e339364
ToppCell	Bronchial-NucSeq-Endothelial-Endothelia_lymphatic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MAGI1 ADCY4 KALRN PIEZO2 LOXHD1 PCSK6 EPB41L2	1.92e-06	198	130	7	fc4b7c3ad52bc5c8b40fa04a156bfbb58afa2872
ToppCell	mild-cDC\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	TET2 ARHGAP5 OTOF CTSH HOMER2 EPB41L2 MCOLN2	2.06e-06	200	130	7	86f585bf9066b179bbcbc703bf43f15da4a07284
ToppCell	COVID_vent-Lymphocytic-Plasma_cell-IgG_Plasmablast\|COVID_vent / Disease condition, Lineage, Cell class and subclass	IGKV1-39 IGKV1-33 EPRS1 BUB1 IGKV1D-39 IGKV1D-33 TOP2A	2.06e-06	200	130	7	fee909730133ec9875e14f7deed2a351dd21dba4
ToppCell	Parenchyma_Control_(B.)-Stromal-TX-Fibroblasts-1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	USP53 PIEZO2 SETBP1 ANGPTL4 MMP2 NEXN EPB41L2	2.06e-06	200	130	7	aa1a35dcca3b799241eef4237f6eb94660e019f0
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	USP53 PIEZO2 SETBP1 ANGPTL4 MMP2 NEXN EPB41L2	2.06e-06	200	130	7	a510deaada669e690329183e18df02870bd204b3
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	USP53 PIEZO2 SETBP1 ANGPTL4 MMP2 NEXN EPB41L2	2.06e-06	200	130	7	dd4228cbed8a4395166a6332e08d44d88bebe3b9
ToppCell	COVID-19-Epithelial_cells-Airway_mucous\|COVID-19 / group, cell type (main and fine annotations)	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	5.48e-06	151	130	6	8216462e723fec2797387929dde095370947e10a
ToppCell	10x5'-GI_large-bowel\|World / Manually curated celltypes from each tissue	IGKV1-39 IGKV1-16 KCNB2 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.01e-05	168	130	6	1290c909655bc37f6b8bf216d18127a21b99e9c0
ToppCell	3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	USP53 KCNB2 GXYLT2 MMP2 DCLK1 EPB41L2	1.15e-05	172	130	6	e37c0b5b547a7345179ab258dd2141fec7064c17
ToppCell	Control-Lymphoid-B_Plasma\|Control / Disease state, Lineage and Cell class	IGKV1-39 IGKV1-16 IGKV1D-43 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.15e-05	172	130	6	61e33836b8cb0f347f3e699eb587a37073b6fa4c
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-T_lymphocytic-regulatory_T_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ASXL1 GPR19 HABP4 FANK1 CPNE1 BTG4	1.31e-05	176	130	6	856a8c4211ea33d926b18d8959a03909562aa563
ToppCell	Control-Neuronal_cells-Neuronal_cells\|Control / group, cell type (main and fine annotations)	MAGI1 ADCY4 KALRN PIEZO2 PCSK6 EPB41L2	1.31e-05	176	130	6	98c07d26ba0dc0fe15ca0ea81f633d4591782bd1
ToppCell	Control-Neuronal_cells\|Control / group, cell type (main and fine annotations)	MAGI1 ADCY4 KALRN PIEZO2 PCSK6 EPB41L2	1.31e-05	176	130	6	c29d09ecf0eb17f767d78af4b7f2e7725c967ff8
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ABCA13 HMGA2 LGI2 WDFY3 MCTP2 DNAH11	1.31e-05	176	130	6	327a3e81b724252e36d786de92a3ffd721ea6d7b
ToppCell	IPF-Lymphoid-B_Plasma\|IPF / Disease state, Lineage and Cell class	IGKV1-39 IGKV1-33 IGKV1D-43 IGKV1D-39 IGKV1D-33 IGKV1D-16	1.31e-05	176	130	6	e4f33f6cd140dd4fa3002bcd65ac8005d27865d1
ToppCell	droplet-Liver-LIVER_HEP-30m-Myeloid-Kupffer_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAK BMPR2 LNPEP UGT8 WDFY3 DCLK1	1.36e-05	177	130	6	14fb8d182775dfd0e49aa7e4e12543a85b3b8bd6
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGKV1-39 IGKV1-33 IGKV1-16 UGT2B17 IGKV1D-39 IGKV1D-16	1.45e-05	179	130	6	494febe77c6d4e6a2c6f0928bbf4c84b0301f188
ToppCell	ASK454-Endothelial-Lymphatic\|ASK454 / Donor, Lineage and Cell class of Lung cells from Dropseq	GON4L PIEZO2 HEBP1 MMP2 FSCN1 GARRE1	1.45e-05	179	130	6	fd84a79f76a01c0377dff5b20016b004d369f96f
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)-Multiciliated_(nasal)_L.0.3.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CES1 ABCA13 CES2 LRRIQ1 DNAH9 DNAH11	1.49e-05	180	130	6	1f1af4474f3f0ac3c0d6b1a6c875c354d36d8eec
ToppCell	Control-Epithelial_cells-Airway_ciliated\|Control / group, cell type (main and fine annotations)	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.59e-05	182	130	6	fb725d10d9ed25dfc6d5bb69cfef78513f7d3e8f
ToppCell	10x5'-Lung-Lymphocytic_B\|Lung / Manually curated celltypes from each tissue	IGKV1-39 IGKV1-16 SETBP1 UGT8 IGKV1D-39 IGKV1D-33	1.59e-05	182	130	6	310f94437d197eaaaf6e30e68063b33e94befe77
ToppCell	5'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating-Lymphatic_EC_differentiating_L.2.5.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAGI1 ADCY4 KALRN PIEZO2 FSCN1 EPB41L2	1.64e-05	183	130	6	4d16bfbadf2cd13008c35e23dd2b5b4ecf92ee11
ToppCell	droplet-Lung-18m-Hematologic-myeloid-classical_monocyte_proliferating\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	APOO ABCA13 ADORA2B BUB1 CAPRIN2 TOP2A	1.64e-05	183	130	6	6c1d7ce60e67bf1df364a4e177c351e7313eb41f
ToppCell	Children_(3_yrs)-Epithelial-ciliated_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.69e-05	184	130	6	5daff849625f2f41d56615569c0ed59cd733b34c
ToppCell	COVID-19-Epithelial_cells-Airway_ciliated\|COVID-19 / group, cell type (main and fine annotations)	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.74e-05	185	130	6	18a40f0a338aa398d81384b5159fb80ce8a2020c
ToppCell	P28-Epithelial-airway_epithelial_cell-club_cell\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	MAK FANK1 LRRIQ1 UGT8 DNAH9 DNAH11	1.80e-05	186	130	6	a26811481668fa25c48a064a56c198685693ad8d
ToppCell	Ciliated_cells-B-IPF_01\|World / lung cells shred on cell class, cell subclass, sample id	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.80e-05	186	130	6	f72267d533fd0c5280d9741ceee3dd116300a7e4
ToppCell	5'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAGI1 ADCY4 KALRN PIEZO2 FSCN1 EPB41L2	1.80e-05	186	130	6	40070d9cd20188ba49b32acfca9bc16256b38bf5
ToppCell	mild_COVID-19_(asymptomatic)-gd_T\|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2)	PCDHGB7 GXYLT2 SYNGR1 MCTP2 KLRC3 MCOLN2	1.80e-05	186	130	6	5fa3ed834898aa06aae15a8ade7ab93a6e4744f8
ToppCell	P28-Epithelial-airway_epithelial_cell\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	MAK FANK1 LRRIQ1 UGT8 DNAH9 DNAH11	1.80e-05	186	130	6	df80f101954b8ec6ccdb03e702de22e70b65181f
ToppCell	368C-Lymphocytic-NK_cells-NK_cell_D3\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	IGKV1-39 TTF2 WDR70 ARHGAP5 PCSK6 MAPK1	1.85e-05	187	130	6	c667fae6440dc98072b584f203d00f0fb1cb2f21
ToppCell	Epithelial-ciliated_cell\|World / Lineage, Cell type, age group and donor	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.91e-05	188	130	6	61a459f3fe57e5728efc72637ff2edc2d343492b
ToppCell	21-Trachea-Epithelial-Multiciliated_cell\|Trachea / Age, Tissue, Lineage and Cell class	DCDC1 CES1 FANK1 LRRIQ1 DNAH9 DNAH11	1.91e-05	188	130	6	803bf76a85b3033d2a04b08dd2c03ce9c15529ba
ToppCell	Adult-Epithelial-ciliated_cell-D231\|Adult / Lineage, Cell type, age group and donor	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.91e-05	188	130	6	34b11f72ca73153d02edcd09b38983ad1a504659
ToppCell	Children_(3_yrs)-Epithelial-ciliated_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.91e-05	188	130	6	2b6dfc88be9ded7b88da9fe78a9cd9f9b3af8af3
ToppCell	COPD-Multiplet-Multiplet\|World / Disease state, Lineage and Cell class	MAGI1 ASXL1 LRRIQ1 MCTP2 DNAH9 TOP2A	1.91e-05	188	130	6	186fe1ea328c942910190a4240262c0d8642ea3b
ToppCell	Children_(3_yrs)-Epithelial-ciliated_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.97e-05	189	130	6	68a3cf7763d6f9b95d6d6524eff7a16042703f1d
ToppCell	Control-Epithelial-Ciliated\|Control / Disease state, Lineage and Cell class	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.97e-05	189	130	6	c007fccd08728db3ea99af9da91d67b9b16dabb3
ToppCell	severe_COVID-19-Plasmablast\|severe_COVID-19 / disease group, cell group and cell class (v2)	IGKV1-39 BUB1 UNC13C IGKV1D-39 DEPDC1B TOP2A	1.97e-05	189	130	6	953143b2c2e87a4d8ef033a5fbb155fe62e9c78e
ToppCell	renal_medulla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	MAGI1 APOO KANSL1 SETBP1 UGT8 WDFY3	1.97e-05	189	130	6	830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCell	Adult-Epithelial-ciliated_cell\|Adult / Lineage, Cell type, age group and donor	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.97e-05	189	130	6	b679920f0993e917dd86da082113bfbd85ea1ca5
ToppCell	COVID-19-lung-Ciliated\|lung / Disease (COVID-19 only), tissue and cell type	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.97e-05	189	130	6	27329c4661aebabd19fac7fe5dca263fe99d76f3
ToppCell	COPD-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	1.97e-05	189	130	6	3e77883db34722b9ce0a03ea74caefc92dc7feff
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	APOO ABCA13 GCM1 LGI2 MCTP2 DNAH11	1.97e-05	189	130	6	bd91bdfe35294e60d980259b70fe9e60dca2743f
ToppCell	Nasal_Brush-Epithelial-Ciliated_2\|Nasal_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X	DCDC1 CES1 FANK1 LRRIQ1 DNAH9 DNAH11	2.02e-05	190	130	6	9ce7df056bfb24d70db4c3c4a2c57d89115de877
ToppCell	Nasal_Brush-Epithelial-Ciliated_2\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	DCDC1 CES1 FANK1 LRRIQ1 DNAH9 DNAH11	2.02e-05	190	130	6	833481ace2800354712e2ce709d5cdfd0aed3d42
ToppCell	5'-Adult-LargeIntestine-Hematopoietic\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGKV1-39 IGKV1-16 IGKV1D-43 IGKV1D-39 IGKV1D-16 KLRC3	2.09e-05	191	130	6	d1d30279ed4612b4f62c225d9eabf0b8a7a09d11
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	KALRN GXYLT2 PIEZO2 NEXN DCLK1 EPB41L2	2.09e-05	191	130	6	107113b930d9ad171f1b2aa20df4567c94fae7d8
ToppCell	nucseq-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.09e-05	191	130	6	e417bf491f8b8d7838a61f7f4f6b1740ba97aa3f
ToppCell	nucseq-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.09e-05	191	130	6	9d31c8424d35bdc0c27188b68bfd0f731af3600b
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	KALRN GXYLT2 PIEZO2 NEXN DCLK1 EPB41L2	2.09e-05	191	130	6	bc353a79a1d11ca52bba5e3874a80d432e1a7715
ToppCell	nucseq-Epithelial-Epithelial_Airway\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.09e-05	191	130	6	1c528f72c9ef3ef3a850b05e4a9715190832270c
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	GXYLT2 PIEZO2 SETBP1 MN1 DCLK1 EPB41L2	2.15e-05	192	130	6	8d56e360ebc624ca4cd7f0af4f3cc599c244f134
ToppCell	human_hepatoblastoma-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	ASXL1 WDR70 MED13L KANSL1 SCAF11 PHIP	2.15e-05	192	130	6	916fbec1c7ab7969bda711886ac88e877e30c280
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	GXYLT2 PIEZO2 SETBP1 MMP2 MN1 DCLK1	2.15e-05	192	130	6	e0f4e4470a71bfa81d9dcd8594e5f82aafc24f81
ToppCell	15-Trachea-Epithelial-Intermediate_ciliated\|Trachea / Age, Tissue, Lineage and Cell class	CES1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.15e-05	192	130	6	9cbe961a800c981cdc742a47ed18e9c8eb6430bd
ToppCell	COPD-Epithelial-Ciliated\|World / Disease state, Lineage and Cell class	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.15e-05	192	130	6	eab1105cd1a98cfcd3d74dc5c9b89e1799bba59e
ToppCell	COPD-Endothelial-Lymphatic\|World / Disease state, Lineage and Cell class	MAGI1 ADCY4 KALRN PIEZO2 PCSK6 FSCN1	2.21e-05	193	130	6	25bdc557055b5bce6a21f8696b48e991c696b979
ToppCell	3'-Broncho-tracheal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.3\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.21e-05	193	130	6	e1b76102f812c433195d1e8811fdd3293a7bc22e
ToppCell	COPD-Endothelial-Lymphatic\|COPD / Disease state, Lineage and Cell class	MAGI1 ADCY4 KALRN PIEZO2 PCSK6 FSCN1	2.21e-05	193	130	6	18bcf08068a236c4575c7a07181ac893dfdcbeeb
ToppCell	Control-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.21e-05	193	130	6	0e37d454f3735edd936ee9a5f5f516ac3aad400e
ToppCell	Control-Endothelial-Lymphatic\|Control / Disease state, Lineage and Cell class	MAGI1 ADCY4 KALRN PIEZO2 PCSK6 FSCN1	2.21e-05	193	130	6	64d19be73e5432d491436a01da5de5c926b615a9
ToppCell	Bronchial_Biopsy-Epithelial-Ciliated_1\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	DCDC1 CES1 FANK1 LRRIQ1 DNAH9 DNAH11	2.21e-05	193	130	6	0b62a6ddd7c42efd9f39781971d1438501e1fa8d
ToppCell	human_hepatoblastoma\|World / Sample and Cell Type and Tumor Cluster (all cells)	ASXL1 WDR70 MED13L KANSL1 SCAF11 PHIP	2.21e-05	193	130	6	e6a688bc834f845ff64dae1be64f073eec5091a1
ToppCell	wk_20-22-Epithelial-Proximal_epithelial-MUC16+_ciliated\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.28e-05	194	130	6	756082a0f5953b52229bb60d40b84701cb6cb23d
ToppCell	droplet-Lung-18m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l1\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	GXYLT2 LGI2 MMP2 MN1 HOMER2 DCLK1	2.28e-05	194	130	6	5594f7437448cb4b37d2d100f44d30c4a367df26
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	ITGB2 SETBP1 SYNGR1 MAPK1 KLRC3 MCOLN2	2.28e-05	194	130	6	24837a27b0041fe8c348225fa8b09b127d743603
ToppCell	Bronchial_Brush-Epithelial-Ciliated_1\|Bronchial_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X	DCDC1 CES1 FANK1 LRRIQ1 DNAH9 DNAH11	2.28e-05	194	130	6	b4ce60c06568123008b1081d644733cb91c28f51
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	GXYLT2 PIEZO2 SETBP1 MN1 DCLK1 EPB41L2	2.28e-05	194	130	6	439d3f17c1f4736122b330e98add9292c7036a8e
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGKV1-39 IGKV1-16 UGT2B17 IGKV1D-43 IGKV1D-39 IGKV1D-16	2.28e-05	194	130	6	6ef4aeb8d8e35e4df58ff2a8256caa2113291de9
ToppCell	Control-Epithelial-Ciliated\|World / Disease state, Lineage and Cell class	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.28e-05	194	130	6	958e648138676d46698090b4046cb484083ae449
ToppCell	Bronchial_Brush-Epithelial-Ciliated_1\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	DCDC1 CES1 FANK1 LRRIQ1 DNAH9 DNAH11	2.28e-05	194	130	6	7a7ddccfe72a4a0dc4d1a5c809988f0069f9f1a3
ToppCell	3'-Broncho-tracheal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.28e-05	194	130	6	4a2c127c90d1fefe604fcb9e796577d21b489dd6
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c07-TYROBP\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	ITGB2 SETBP1 SYNGR1 MAPK1 MCTP2 KLRC3	2.28e-05	194	130	6	52e09b14159b609af00264a8f38accf37ba8f464
ToppCell	COVID-19-Epithelial-Ciliated_cells\|COVID-19 / Condition, Lineage and Cell class	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.28e-05	194	130	6	43be5fbd51dd58839cb03ca3ddd05a458e1ddb74
ToppCell	IPF-Multiplet-Multiplet\|IPF / Disease state, Lineage and Cell class	MAGI1 DCDC1 FANK1 LRRIQ1 DNAH9 DNAH11	2.34e-05	195	130	6	fce0c29574bb7aab181b9c00feb42681e285d1f2
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DCDC1 ABCA13 FANK1 LRRIQ1 DNAH9 DNAH11	2.34e-05	195	130	6	649fd2336e963f6a150d182a53ad5dd838ca80b1
ToppCell	Parenchymal-10x3prime_v2-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	IGKV1-39 IGKV1-16 UGT2B17 IGKV1D-39 IGKV1D-33 IGKV1D-16	2.34e-05	195	130	6	2d18f08f33f3b261c77b8adf87d1a184cc6d7400
ToppCell	IPF-Multiplet-Multiplet\|World / Disease state, Lineage and Cell class	MAGI1 DCDC1 FANK1 LRRIQ1 DNAH9 DNAH11	2.34e-05	195	130	6	21dbdc803c6947024dc2416e9e21c2ef0af9bc31
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.2.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	USP53 GXYLT2 PIEZO2 MMP2 DCLK1 EPB41L2	2.34e-05	195	130	6	f54bc4454270ff06e85596f98199372b50d0179f
ToppCell	IPF-Multiplet\|IPF / Disease state, Lineage and Cell class	MAGI1 DCDC1 FANK1 LRRIQ1 DNAH9 DNAH11	2.34e-05	195	130	6	eacc0449ae6f3ad8002268cd061467684c6fb9a7
Drug	ecgonine methyl ester	CES1 GCM1 HUWE1 CES2 FGA MMP2	9.17e-06	91	121	6	CID000104904
Drug	p-nitrophenyl caproate	HFE CES1 CES2	1.20e-05	9	121	3	CID000567162
Drug	SN-38G	ABCC1 CES1 CES2 UGT2B15 UGT2B17	1.55e-05	59	121	5	CID000443154
Drug	3',4'-dihydroxyflavone	ABCC1 MMP2 MAPK1	2.34e-05	11	121	3	ctd:C028288
Drug	prostaglandin E2 glyceryl ester	CES1 CES2 MAPK1	2.34e-05	11	121	3	ctd:C518978
Drug	5-iodoisatin	CES1 CES2	2.80e-05	2	121	2	CID000088695
Drug	5-chloro-7-methylisatin	CES1 CES2	2.80e-05	2	121	2	CID000366710
Drug	I08-742	CES1 CES2	2.80e-05	2	121	2	CID002786143
Drug	3,3'-dimethoxybenzil	CES1 CES2	2.80e-05	2	121	2	CID000123493
Drug	tolserine	CES1 CES2	2.80e-05	2	121	2	ctd:C412047
Drug	NSC-379518	CES1 CES2	2.80e-05	2	121	2	CID000137905
Drug	aceanthrenequinone	CES1 CES2	2.80e-05	2	121	2	CID000316765
Drug	7-trifluoromethylisatin	CES1 CES2	2.80e-05	2	121	2	CID000604575
Drug	5-chloroisatin	CES1 CES2	2.80e-05	2	121	2	CID000087203
Drug	4-Chlorobenzil	CES1 CES2	2.80e-05	2	121	2	CID000089801
Drug	4,5-dichloro-1H-indole-2,3-dione	CES1 CES2	2.80e-05	2	121	2	CID005139980
Drug	p-methylbenzil	CES1 CES2	2.80e-05	2	121	2	CID000075511
Drug	AC1Q27R1	CES1 CES2	2.80e-05	2	121	2	CID000087502
Drug	AC1M2MWF	CES1 CES2	2.80e-05	2	121	2	CID002147394
Drug	d18-75	CES1 CES2	2.80e-05	2	121	2	CID000076996
Drug	NSC 408976	CES1 CES2	2.80e-05	2	121	2	CID000101375
Drug	2,2'-Dichlorobenzil	CES1 CES2	2.80e-05	2	121	2	CID000089076
Drug	6-chloro-7-methyl-1H-indole-2,3-dione	CES1 CES2	2.80e-05	2	121	2	CID004513067
Drug	5,7-dichloroisatin	CES1 CES2	2.80e-05	2	121	2	CID000080771
Drug	p-methoxybenzil	CES1 CES2	2.80e-05	2	121	2	CID000031494
Drug	AC1N9FPX	CES1 CES2	2.80e-05	2	121	2	CID004384851
Drug	4-nitrobenzil	CES1 CES2	2.80e-05	2	121	2	CID000283893
Drug	chloroisatin	CES1 CES2	2.80e-05	2	121	2	CID000137777
Drug	4-chloro-7-methyl-1h-indole-2,3-dione	CES1 CES2	2.80e-05	2	121	2	CID001810509
Drug	acetaldophosphamide	CES1 CES2	2.80e-05	2	121	2	CID000163905
Drug	4,4'-Difluorobenzil	CES1 CES2	2.80e-05	2	121	2	CID000123072
Drug	4,4'-Dichlorobenzil	CES1 CES2	2.80e-05	2	121	2	CID000018946
Drug	1-laurylisatin	CES1 CES2	2.80e-05	2	121	2	CID001897797
Drug	1-cetylisatin	CES1 CES2	2.80e-05	2	121	2	CID003772674
Drug	AC1M5V1J	CES1 CES2	2.80e-05	2	121	2	CID002385967
Drug	DNC005462	CES1 CES2	2.80e-05	2	121	2	CID011437501
Drug	2-nitrophenylacetic acid	CES1 CES2	2.80e-05	2	121	2	ctd:C119971
Drug	DNC005463	CES1 CES2	2.80e-05	2	121	2	CID011392969
Drug	AC1MS20N	CES1 CES2	2.80e-05	2	121	2	CID003527426
Drug	9-amino-6-chloro-2-methoxyacridine	CES1 CES2	2.80e-05	2	121	2	ctd:C010847
Drug	1,2-bis(4-nitrophenyl)ethane-1,2-dione	CES1 CES2	2.80e-05	2	121	2	CID001812008
Drug	4-amino-2,6-dimethylphenol	CES1 CES2	2.80e-05	2	121	2	CID000082667
Drug	2-chloro-3',4'-dimeth-oxy-benzil	CES1 CES2	2.80e-05	2	121	2	CID000092036
Drug	4,7-dichloroisatin	CES1 CES2	2.80e-05	2	121	2	CID002734793
Drug	4,6-dichloro-1h-indole-2,3-dione	CES1 CES2	2.80e-05	2	121	2	CID000251908
Drug	AC1LWPKX	CES1 CES2	2.80e-05	2	121	2	CID001755771
Drug	AC1Q2DS8	CES1 CES2	2.80e-05	2	121	2	CID002427416
Drug	1,2-dicyclohexylethane-1,2-dione	CES1 CES2	2.80e-05	2	121	2	CID011806279
Drug	DP00565	CES1 CES2	2.80e-05	2	121	2	CID002777298
Drug	diethyl fluoromalonate	CES1 CES2	2.80e-05	2	121	2	CID000012702
Drug	anisil	CES1 CES2	2.80e-05	2	121	2	CID000071043
Drug	4-chloroisatin	CES1 CES2	2.80e-05	2	121	2	CID000096047
Drug	6-O-monoacetylmorphine	CES1 CES2	2.80e-05	2	121	2	ctd:C026979
Drug	NNMP	CES1 CES2	2.80e-05	2	121	2	CID000146767
Drug	aniracetam	CES1 CES2	2.80e-05	2	121	2	ctd:C036466
Drug	AC1Q24Z2	CES1 CES2	2.80e-05	2	121	2	CID004338240
Drug	1-benzyl-1h-indole-2,3-dione	CES1 CES2	2.80e-05	2	121	2	CID000264734
Drug	prolyl-beta-naphthylamide	CES1 CES2	2.80e-05	2	121	2	CID000167505
Drug	5-(Trifluoro-meth-oxy)isatin	CES1 CES2	2.80e-05	2	121	2	CID002732752
Drug	hostacain	CES1 CES2	2.80e-05	2	121	2	CID000022378
Drug	phenethylcymserine	CES1 CES2	2.80e-05	2	121	2	ctd:C576198
Drug	5,6-dichloro-1H-indole-2,3-dione	CES1 CES2	2.80e-05	2	121	2	CID011009341
Drug	4-nitrophenylacetic acid	CES1 CES2	2.80e-05	2	121	2	ctd:C118008
Drug	AC1MBV04	CES1 CES2	2.80e-05	2	121	2	CID002731732
Drug	AC1N4VNK	CES1 CES2	2.80e-05	2	121	2	CID004135273
Drug	acetyl-11-ketoboswellic acid	MMP2 MAPK1 TOP2A	4.03e-05	13	121	3	ctd:C094432
Drug	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester	CES1 CES2 MAPK1	5.11e-05	14	121	3	ctd:C500528
Drug	2-naphthol	ABCC1 CES1 UGT2B15	6.36e-05	15	121	3	ctd:C028405
Drug	Rauwolscine hydrochloride [6211-32-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A	HFE ABCC1 ASXL1 LNPEP CAPRIN2 FSCN1 DNAJB2	7.15e-05	190	121	7	6274_DN
Drug	Dizocilpine maleate [77086-22-7]; Down 200; 11.8uM; MCF7; HT_HG-U133A	EPRS1 ITCH BUB1 CD58 KCNS3 MAPK1 GNS	7.63e-05	192	121	7	6223_DN
Drug	Atropine sulfate monohydrate [5908-99-6]; Down 200; 5.8uM; HL60; HG-U133A	HFE TTF2 RBM26 ACTL6A ATXN7 WDFY3 CTSH	7.89e-05	193	121	7	1768_DN
Drug	Cyclosporin A [59865-13-3]; Down 200; 3.4uM; MCF7; HT_HG-U133A	HFE GPR19 ST3GAL5 PCSK6 KCNS3 WDFY3 FSCN1	8.15e-05	194	121	7	4411_DN
Drug	2-tridecanol	CES1 CES2	8.37e-05	3	121	2	CID000015449
Drug	indandione	CES1 CES2	8.37e-05	3	121	2	CID000123358
Drug	5-bromoindoxyl acetate	CES1 CES2	8.37e-05	3	121	2	CID000087075
Drug	AC1L7MWY	CES1 CES2	8.37e-05	3	121	2	CID000313189
Drug	cyclohexyl hexadecanoate	CES1 CES2	8.37e-05	3	121	2	CID000074288
Drug	AC1Q2MLF	CES1 CES2	8.37e-05	3	121	2	CID002305233
Drug	1,7-N-heptylene-bis-9,9'-amino-1,2,3,4-tetrahydroacridine	CES1 CES2	8.37e-05	3	121	2	ctd:C122128
Drug	5-bromisatin	CES1 CES2	8.37e-05	3	121	2	CID000006889
Drug	nordalbergin	CES1 CES2	8.37e-05	3	121	2	CID005320203
Drug	NACPC	CES1 CES2	8.37e-05	3	121	2	CID000175510
Drug	AMD 6221	ITGB2 MMP2	8.37e-05	3	121	2	ctd:C453459
Drug	NNMBz	CES1 CES2	8.37e-05	3	121	2	CID000124353
Drug	AC1Q6FL6	CES1 CES2	8.37e-05	3	121	2	CID003821945
Drug	ACE co	CES1 CES2	8.37e-05	3	121	2	CID000163966
Drug	N-methylisatin	CES1 CES2	8.37e-05	3	121	2	CID000016358
Drug	AC1Q2IW1	CES1 CES2	8.37e-05	3	121	2	CID001713189
Drug	ethyl pentanoate	CES1 CES2	8.37e-05	3	121	2	CID000010882
Drug	1-(2-bromoethyl)-1H-indole-2,3-dione	CES1 CES2	8.37e-05	3	121	2	CID003542734
Drug	6-bromo-5-methyl-1H-indole-2,3-dione	CES1 CES2	8.37e-05	3	121	2	CID001718647
Drug	AC1MBTQK	CES1 CES2	8.37e-05	3	121	2	CID002731127
Drug	5'-deoxy-5-fluorocytidine	CES1 CES2	8.37e-05	3	121	2	ctd:C418208
Drug	diphenyl methyl phosphate	CES1 CES2	8.37e-05	3	121	2	CID000008291
Drug	riboflavin-5'-monobutyrate	CES1 CES2	8.37e-05	3	121	2	CID000189057
Drug	tributyl phosphite	CES1 CES2	8.37e-05	3	121	2	CID000007623
Drug	2,2-dimethylpropyl methylphosphonofluoridate	CES1 CES2	8.37e-05	3	121	2	CID000574378
Drug	7-Chloro-indoline-2,3-dione	CES1 CES2	8.37e-05	3	121	2	CID000344135
Drug	bis(tBu-SATE)PMEA	CES1 CES2	8.37e-05	3	121	2	CID000464177
Drug	Methoxypropanol acetate	CES1 CES2	8.37e-05	3	121	2	CID003033863
Disease	behavioural disinhibition measurement	NDUFAF5 UNC13C MMP2 DNAH9 DNAH11	1.78e-05	75	126	5	EFO_0006946
Disease	Colorectal Carcinoma	TET2 ABCC1 KALRN ABCA13 KCNB2 SETBP1 BUB1 MMP2 FOXH1 CTSH PHIP DCLK1	4.93e-05	702	126	12	C0009402
Disease	cholic acid glucuronide measurement	UGT2B15 UGT2B17	5.41e-05	3	126	2	EFO_0800574
Disease	phospholipids:total lipids ratio, high density lipoprotein cholesterol measurement	NPEPPS KCNB2 KANSL1 PCSK6 ANGPTL4 UGT2B15 UGT2B17 DNAH11	5.44e-05	307	126	8	EFO_0004612, EFO_0020946
Disease	high density lipoprotein particle size measurement	CES1 CES2 KANSL1 ANGPTL4 UGT2B15 UGT2B17	9.32e-05	170	126	6	EFO_0008592
Disease	Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease	TET2 ASXL1	1.08e-04	4	126	2	C1301365
Disease	X-25937 measurement	UGT2B15 UGT2B17	1.08e-04	4	126	2	EFO_0800937
Disease	X-24947 measurement	UGT2B15 UGT2B17 ACSM6	1.10e-04	22	126	3	EFO_0800910
Disease	omega-3 polyunsaturated fatty acid measurement	WDR70 KANSL1 ANGPTL4 UGT2B15 UGT2B17	1.56e-04	118	126	5	EFO_0010119
Disease	Myelodysplastic syndrome	TET2 ASXL1	1.79e-04	5	126	2	cv:C3463824
Disease	MYELODYSPLASTIC SYNDROME	TET2 ASXL1	1.79e-04	5	126	2	614286
Disease	chronic myelomonocytic leukemia (is_implicated_in)	TET2 ASXL1	1.79e-04	5	126	2	DOID:0080188 (is_implicated_in)
Disease	MYELODYSPLASTIC SYNDROME	HFE TET2 ASXL1 SETBP1	1.97e-04	67	126	4	C3463824
Disease	Hematopoetic Myelodysplasia	HFE TET2 ASXL1	2.56e-04	29	126	3	C2713368
Disease	pulmonary emphysema (biomarker_via_orthology)	FGA MMP2	2.68e-04	6	126	2	DOID:9675 (biomarker_via_orthology)
Disease	myelodysplastic syndrome (is_implicated_in)	HFE TET2 ASXL1	2.84e-04	30	126	3	DOID:0050908 (is_implicated_in)
Disease	Profound Mental Retardation	GON4L MED13L KANSL1 SETBP1 PHIP	3.34e-04	139	126	5	C0020796
Disease	Mental Retardation, Psychosocial	GON4L MED13L KANSL1 SETBP1 PHIP	3.34e-04	139	126	5	C0025363
Disease	Mental deficiency	GON4L MED13L KANSL1 SETBP1 PHIP	3.34e-04	139	126	5	C0917816
Disease	keratoconus (is_marker_for)	FGA MMP2	3.75e-04	7	126	2	DOID:10126 (is_marker_for)
Disease	X-24574 measurement	UGT2B15 UGT2B17	3.75e-04	7	126	2	EFO_0800897
Disease	uveal melanoma disease severity	MAGI1 WDR70	3.75e-04	7	126	2	EFO_0010244
Disease	deoxycholic acid glucuronide measurement	UGT2B15 UGT2B17	4.98e-04	8	126	2	EFO_0800575
Disease	myelofibrosis (is_implicated_in)	HFE ASXL1	4.98e-04	8	126	2	DOID:4971 (is_implicated_in)
Disease	visceral heterotaxy (implicated_via_orthology)	MMP21 FOXH1 DNAH11	5.31e-04	37	126	3	DOID:0050545 (implicated_via_orthology)
Disease	cholesteryl esters:total lipids ratio, high density lipoprotein cholesterol measurement	CES1 CES2 PCSK6 ANGPTL4 UGT2B15 UGT2B17	6.34e-04	243	126	6	EFO_0004612, EFO_0020944
Disease	Situs ambiguous	MMP21 DNAH9	6.39e-04	9	126	2	C1167664
Disease	Intellectual Disability	GON4L ACTL6A MED13L KANSL1 ST3GAL5 SETBP1 MN1 PHIP	6.90e-04	447	126	8	C3714756
Disease	Tumoral calcinosis	RIPK3 ITGB2 MMP2	7.73e-04	42	126	3	C0263628
Disease	Calcinosis	RIPK3 ITGB2 MMP2	7.73e-04	42	126	3	C0006663
Disease	Microcalcification	RIPK3 ITGB2 MMP2	7.73e-04	42	126	3	C0521174
Disease	4-androsten-3alpha,17alpha-diol monosulfate (3) measurement	UGT2B15 UGT2B17	7.96e-04	10	126	2	EFO_0022090
Disease	Peripheral T-Cell Lymphoma	TET2 CD58	7.96e-04	10	126	2	C0079774
Disease	Leukemia, Myelocytic, Acute	TET2 SETBP1 SYNGR1 CTSH MN1	9.01e-04	173	126	5	C0023467
Disease	sexual dimorphism measurement	TET2 ADCY4 ITCH RIPK3 NPEPPS WDR70 KCNB2 HMGA2 ANGPTL4 CPNE1 PHIP HOMER2 EPB41L2	9.17e-04	1106	126	13	EFO_0021796
Disease	Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement	KCNB2 DNAH11	9.70e-04	11	126	2	EFO_0009923
Disease	DNA repair protein RAD51 homolog 4 measurement	UGT2B15 UGT2B17	9.70e-04	11	126	2	EFO_0801531
Disease	Situs Inversus	MMP21 DNAH9	9.70e-04	11	126	2	C0037221
Disease	Acute Promyelocytic Leukemia	TET2 ASXL1 ITGB2	1.01e-03	46	126	3	C0023487
Disease	5alpha-androstan-3beta,17beta-diol monosulfate (2) measurement	UGT2B15 UGT2B17	1.16e-03	12	126	2	EFO_0800291
Disease	Colorectal Neoplasms	TET2 ABCC1 ABCA13 BUB1 MMP2 DCLK1	1.25e-03	277	126	6	C0009404
Disease	omega-6:omega-3 polyunsaturated fatty acid ratio	KANSL1 UGT2B15 UGT2B17	1.29e-03	50	126	3	EFO_0010732
Disease	Erythrocyte Mean Corpuscular Hemoglobin Test	HFE HADHB	1.37e-03	13	126	2	C0369183
Disease	androstenediol (3alpha, 17alpha) monosulfate (3) measurement	UGT2B15 UGT2B17	1.37e-03	13	126	2	EFO_0800293
Disease	Finding of Mean Corpuscular Hemoglobin	HFE HADHB	1.37e-03	13	126	2	C1261502
Disease	X-19141 measurement	UGT2B15 UGT2B17	1.37e-03	13	126	2	EFO_0800799
Disease	alcohol use disorder (implicated_via_orthology)	ACTL6A ANGPTL4 UNC13C GSTO1 HOMER2	1.53e-03	195	126	5	DOID:1574 (implicated_via_orthology)
Disease	Birth Weight	HFE HMGA2	1.59e-03	14	126	2	C0005612
Disease	5alpha-androstan-3alpha,17alpha-diol monosulfate measurement	UGT2B15 UGT2B17	1.59e-03	14	126	2	EFO_0800283
Disease	Cocaine-Related Disorders	CES1 CES2 MAPK1 HOMER2	1.62e-03	117	126	4	C0236736
Disease	brain connectivity measurement	MAGI1 PLSCR5 NPEPPS LRRIQ1 KANSL1 KCNS3 DEPDC1B	1.69e-03	400	126	7	EFO_0005210
Disease	aspartate aminotransferase measurement	CCDC125 HFE MAGI1 MCMBP KALRN STARD10 ERVK13-1 CPNE1 CTSH KLRC3 PHIP	1.74e-03	904	126	11	EFO_0004736
Disease	Situs ambiguus	MMP21 DNAH9	1.83e-03	15	126	2	C0266642
Disease	myelodysplastic syndrome (implicated_via_orthology)	TET2 ASXL1	1.83e-03	15	126	2	DOID:0050908 (implicated_via_orthology)
Disease	obsolete_red blood cell distribution width	HFE ABCC1 ASXL1 KALRN FREM3 BMPR2 FANK1 LOXHD1 KANSL1 ST3GAL5 ATXN7 ANGPTL4 UGT2B15 GARRE1	1.87e-03	1347	126	14	EFO_0005192
Disease	white matter hyperintensity measurement	ABCC1 PLSCR5 GON4L FANK1 ST3GAL5 SETBP1	1.93e-03	302	126	6	EFO_0005665
Disease	neutrophil collagenase measurement	ABCA13 CPNE1	2.09e-03	16	126	2	EFO_0008248
Disease	docosahexaenoic acid measurement	WDR70 KANSL1 UGT2B15 UGT2B17	2.19e-03	127	126	4	EFO_0007761
Disease	Cocaine Abuse	CES1 CES2 MAPK1 HOMER2	2.19e-03	127	126	4	C0009171
Disease	phospholipid measurement, high density lipoprotein cholesterol measurement	CES1 CES2 PCSK6 ANGPTL4 UGT2B15 UGT2B17	2.62e-03	321	126	6	EFO_0004612, EFO_0004639
Disease	glucuronate measurement	MAPK1 DCLK1	2.65e-03	18	126	2	EFO_0010486
Disease	5alpha-androstan-3alpha,17beta-diol monosulfate (1) measurement	UGT2B15 UGT2B17	2.65e-03	18	126	2	EFO_0800288
Disease	triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement	CES1 NPEPPS CES2 PCSK6 ANGPTL4	2.85e-03	225	126	5	EFO_0008317, EFO_0020947
Disease	Juvenile Myelomonocytic Leukemia	ASXL1 SETBP1	2.95e-03	19	126	2	C0349639
Disease	etiocholanolone glucuronide measurement	UGT2B15 UGT2B17	2.95e-03	19	126	2	EFO_0800362
Disease	Cocaine Dependence	CES1 CES2 MAPK1 HOMER2	3.03e-03	139	126	4	C0600427
Disease	ascending aortic diameter	DCDC1 MED13L PIEZO2 HMGA2	3.11e-03	140	126	4	EFO_0021787
Disease	androsterone glucuronide measurement	UGT2B15 UGT2B17	3.27e-03	20	126	2	EFO_0800317
Disease	apolipoprotein A 1 measurement	HFE TET2 CES1 NPEPPS CES2 BMPR2 PCSK6 ANGPTL4 UGT2B15 PHIP	3.52e-03	848	126	10	EFO_0004614
Disease	Dermatologic disorders	MMP21 ATXN7 GSTO1	4.10e-03	75	126	3	C0037274

Protein segments in the cluster

Peptide	Gene	Start	Entry
WLDFKKLIQVAPPKQ	ACSM6	196	Q6P461
FWTNLFAKKAVEKPP	CES1	546	P23141
SRWKPEDAKNPQKNT	AADAT	176	Q8N5Z0
ITKQLPDFNPFKWLK	ERVK13-1	441	Q9NX77
SIPQQRQKLKKGIFW	ANGPTL4	366	Q9BY76
QKFVLKVQKPANPWE	BUB1	816	O43683
VTLFQPAQGKNKPKW	ADORA2B	256	P29275
EAKEKKLAWPINSNP	GPR19	396	Q15760
EGSPANWKRKEKLPQ	ACTL6A	231	O96019
EVVKNNLNPVWRPFK	CPNE3	181	O75131
QKPVWNDLNPKAVTT	DNAH11	2196	Q96DT5
ISKPPTLAKVWYNQK	ABCA13	4386	Q86UQ4
QKQWKQSKDFNPLTL	ADCY4	551	Q8NFM4
NQKDVIKFPEWNDLP	DEPDC1B	121	Q8WUY9
KTKVGLPPLEKFNNW	HADHB	406	P55084
KDEKPNWNQSAPLSK	ASXL1	1031	Q8IXJ9
NFFPRKPKWDKNQIT	MMP2	111	P08253
EFKPPESNQKINARW	RCOR3	276	Q9P2K3
VPTKKTWFDKPNFNR	RBM26	501	Q5T8P6
APWFKKPLKNTSVVD	NEXN	581	Q0ZGT2
KILKQQAPPNTDWRF	PCDHGB7	801	Q9Y5F8
QKKNSRQEAVPWKKP	PNMA8A	246	Q86V59
FQPKQIVKSLIPSWN	OGFOD1	191	Q8N543
NKVPWNRLFPNADSK	MAPK1	271	P28482
KPSNLYKQPNTKRVW	DCDC1	1656	M0R2J8
NWYQQKPGKAPKLLI	IGKV1D-33	56	P01593
NWYQQKPGKAPKLLI	IGKV1D-39	56	P04432
PSNVPLKEVLWKKQK	CD58	46	P19256
NLNPEWNKVFTFPIK	MCTP2	551	Q6DN12
PNKRFKIWQDKQPQL	MED13L	676	Q71F56
KIWQDKQPQLQPLHF	MED13L	681	Q71F56
QKKPDPFKIWAQSRS	MAGI1	786	Q96QZ7
KDPAKPQAKGNFWAV	FOXH1	96	O75593
VININLKNKPEWFFK	GSTO1	51	P78417
WKENFQKPGNVKNSP	APOO	181	Q9BUR5
AWYQQKPAKAPKLFI	IGKV1D-43	56	A0A0B4J1Z2
IDPNTKKNWMPASKQ	HOMER2	16	Q9NSB8
TDEILLNPNNKWFKP	LOXHD1	456	Q8IVV2
LNPNNKWFKPGIIEK	LOXHD1	461	Q8IVV2
PFKKLEYTKNVNPNW	DCLK1	136	O15075
SPEQKNWLDPAKEIK	EPB41L2	266	O43491
WKNLQEQTRPKPEFN	HABP4	296	Q5JVS0
SQVRNPEKQGKLKEW	PCSK6	611	P29122
TQKWDPFLPKFTIQN	PLSCR5	166	A0PG75
QQNSWLPANGLFPKK	MMP21	536	Q8N119
QFWKKALPQKIQELE	CES2	536	O00748
NPQEWKKLFKPCAAQ	GXYLT2	181	A0PJZ3
ALIIKPDNFWQKQKT	KALRN	126	O60229
KSQWQNKPFDKIKPP	KANSL1	686	Q7Z3B3
KKPWQLQGEVTAQKR	MPHOSPH10	381	O00566
KENWNKLVQKFPLGS	LNPEP	946	Q9UIQ6
LAAAPCQKKFWKNPL	KCNS3	241	Q9BQ31
YPQNITMKWLKDKQP	HFE	231	Q30201
HVVWPQPATTKKNKQ	HIPK3	751	Q9H422
AKEQKEVQTPKWITP	HUWE1	1571	Q7Z6Z7
VEKHLNAQLWKKIPP	ATXN7	551	O15265
IKSFKPWLEIFKQNQ	LRRIQ1	746	Q96JM4
KVNPKSSQRKLNWIP	PASD1	11	Q8IV76
EKLKSQWNNDNPLFK	ITGB2	741	P05107
KCNNTNSPKWKQPLT	ITCH	56	Q96J02
RVKKGFDFQWPQPDK	UPF1	741	Q92900
PNKWKFFKGPLNVID	KCNB2	256	Q92953
NPIKENFPFNNPWRK	CCDC125	446	Q86Z20
KKKQIWTLEQPPDEA	FSCN1	41	Q16658
KALQWHPDKNPDNKE	DNAJB2	26	P25686
PFVSPWDKKEEANQK	DHX57	1096	Q6P158
VNQDNKTKTWPPKAP	GARRE1	966	O15063
PKPKNLGNNTKLIEW	UGT8	326	Q16880
NKQLSKVFPETPEKW	HEATR4	381	Q86WZ0
VKLPQNVKKTDWFQE	GCM1	21	Q9NP62
PTWNISPIKKANEIK	GON4L	341	Q3T8J9
EKQRPKFPEAWKENS	BMPR2	456	Q13873
SDPKQIWKFVENFKQ	DHRS12	101	A0PJE2
DWRKKGNFVSPVKNQ	CTSH	121	P09668
EEQKKQETPKLWPVQ	CAPRIN2	486	Q6IMN6
LWPVQLQKEQDPKKQ	CAPRIN2	496	Q6IMN6
LQKEQDPKKQTPKSW	CAPRIN2	501	Q6IMN6
NWDPKKRPTASQALK	MAK	266	P20794
NFKSQLQKVPPEWKA	FGA	236	P02671
KSWQKIQEPNTFPAI	GNS	121	P15586
RKWPQQVVQKKPAQE	HMGA2	81	P52926
AWFQQKPGKAPKSLI	IGKV1-16	56	P04430
NWYQQKPGKAPKLLI	IGKV1-33	56	P01594
NWYQQKPGKAPKLLI	IGKV1-39	56	P01597
TKKFEPWSKLVPQFE	DNAH9	2426	Q9NYC9
WKFAQKVVPDPNVIK	DDX19A	281	Q9NUU7
WSPNKDTPQEKKRPQ	SCAF11	801	Q99590
KNVKPDQWVKLNLGT	NPEPPS	571	P55786
PKAFKIIPALSNWEQ	BYSL	201	Q13895
QDLSKKPPDWKNSSF	MCOLN2	196	Q8IZK6
IKNNLNPTWKRFSVP	CPNE1	181	Q99829
FKEKLKENNAPKWVP	MCMBP	36	Q9BTE3
KENNAPKWVPSLNEV	MCMBP	41	Q9BTE3
KKNPNFNTLVKWFEV	OTOF	1176	Q9HC10
DDKTLAPWEKAKPQN	MN1	1241	Q10571
APWEKAKPQNPNSKE	MN1	1246	Q10571
IVKSPQKEWNPSLFK	ABCC1	301	P33527
LEKKAKRQGPQEQWF	FANK1	31	Q8TC84
DFKWKTNKQIQFNPG	FREM3	1821	P0C091
LVNSQQVPNHKKWLP	RGS21	136	Q2M5E4
KIWAFNKKVIDPVAP	EPRS1	491	P07814
PKWVVNKSSQFLAPK	STARD10	196	Q9Y365
KKARQKSQKSPWQPF	SUPT20HL1	371	Q3ZLR7
PIILQWNKSSKKFVP	LGI2	396	Q8N0V4
FWKQVAEKIPLQPKH	ST3GAL5	291	Q9UNP4
VSLAQDPKWQQRKPK	KLRC3	11	Q07444
KKKTKNFNPPTRRNW	ARHGAP5	1241	Q13017
LKRKQKNWAARQPEP	NDUFAF5	51	Q5TEU4
NNKEPATRFQWKVLP	ERVK-9	1071	P63128
KKARQKSQKSPWQPF	SUPT20HL2	371	P0C7V6
QPFQSWLQIPRKKNV	BTG4	176	Q9NY30
KDPSFSNWPKENPKQ	USP53	621	Q70EK8
EVGRWNNNKKSPIKA	DNTTIP2	371	Q5QJE6
VRESPKKWQPQRQKA	TEX13D	641	A0A0J9YY54
TSNIRKEFVPKWNKP	USP6NL	476	Q92738
KEFVPKWNKPSDVSA	USP6NL	481	Q92738
EQNKVLIPPTWNKTF	WDFY3	3036	Q8IZQ1
TPEPKIKKNNWQSPD	UNC13C	436	Q8NB66
NKIYSINPKKQPWHK	PHIP	981	Q8WWQ0
KVNWDQDPKPALVTK	RIPK3	81	Q9Y572
KKVPFWNVQNKIILF	TMPRSS7	66	Q7RTY8
WEVENPKKQKSVFKP	WDR70	311	Q9NW82
FFPWNKNVEVNKDKP	PIEZO2	1986	Q9H5I5
RKFDKWQEPPPVKQV	PRPF31	326	Q8WWY3
LANQWQVSKPKDNPL	SYNGR1	126	O43759
KNSPWKHQPQGQKVK	TEX13C	921	A0A0J9YWL9
PVKAWKEAQQKVPDE	TOP2A	1086	P11388
KPPRLQWFEQQAKKL	ZNF622	176	Q969S3
PRNELDNPHKQKAWK	TPTE2P1	46	Q5T6R2
NNKEPATRFQWKVLP	ERVK-19	151	Q9WJR5
QIPQKVLWRFDGKKP	UGT2B15	331	P54855
TIPNPDLDWVKNAQK	SETBP1	346	Q9Y6X0
APPENKTWKKVTKQE	TET2	996	Q6N021
QIPQKVLWRFDGKKP	UGT2B17	331	O75795
QALWKFIKPKQPMDS	ZBTB26	121	Q9HCK0
WLRNPFKVLDKNQEP	TTF2	121	Q9UNY4
FKVLDKNQEPALWKQ	TTF2	126	Q9UNY4
KKLKVWFRIPNQFQS	HEBP1	96	Q9NRV9
AWYQQKPEKAPKSLI	IGKV1D-16	56	P01601
SLPNTKFWNGLKNLK	LRRIQ3	86	A6PVS8